ArticleBMC complementary medicine and therapies2026
Association between the subsequent benign prostate hyperplasia-related surgery risk and patients treated with Chinese herbal medicine: a population-based Taiwanese cohort study.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe association of Chinese herbal medicines (CHM) with the decreased risk of benign prostatic hyperplasia (BPH)-related surgery in patients with BPH is limited by the small sample size and short follow-up. We try to address this association in a large national sample using 21 years of data.
methodsA random sample composed of two million beneficiaries with newly diagnosed BPH between 2001 and 2016, followed until 2021 in Taiwan's National Health Insurance Research Database was analyzed with a multivariate Cox proportional-hazards model. After 1:1 propensity score matching by baseline comorbidities, age, and the index year, a total of 11,172 patients were assigned to the CHM group (CHM + Western medicine) and 11,172 patients were assigned to the non-CHM group (Western medicine only). The occurrence of BPH-related surgery during the follow-up period was the primary outcome. The Kaplan-Meier method was used to calculate the cumulative incidence of BPH-related surgery in patients with BPH, both those who received CHM treatment and those who did not.
resultsDuring the study period, 875 CHM users and 870 CHM non-users underwent BPH-related surgery, resulting in surgery incidence rates of 6.89 and 7.26 per 1,000 person-years, respectively. Significantly fewer CHM users than CHM non-users received BPH-related surgery (adjusted HR = 0.89; 95% CI = 0.81, 0.98). A significantly lower risk was observed in those treated with CHM for more than 12 months. Dan Shen and Ji-Sheng-Shen-Qi-Wan were the most commonly prescribed single herb and CHM formula, respectively.
conclusionsOur study demonstrated that CHM may reduce the long-term risk of BPH-related surgery. Co-treatment with CHM reduced the risk of BPH-related surgery, especially in patients using CHM for over a year.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.